Clinical impact of additional findings detected by genome-wide non-invasive prenatal testing: Follow-up results of the TRIDENT-2 study

(The American Journal of Human Genetics 109, 1140–1152; June 2, 2022) In the originally published version of this article, in Table 3, the column heading “Placenta biopsies” was placed erroneously under “Available clinical follow-up” instead of under “Available cytogenic follow-up.” The authors apologize for this error, which has been corrected online. Clinical impact of additional findings detected by genome-wide non-invasive prenatal testing: Follow-up results of the TRIDENT-2 studyvan Prooyen Schuurman et al.The American Journal of Human GeneticsJune 02, 2022In BriefIn the TRIDENT-2 study, all pregnant women in the Netherlands are offered genome-wide non-invasive prenatal testing (GW-NIPT) with a choice of receiving either full screening or screening solely for common trisomies. Previous data showed that GW-NIPT can reliably detect common trisomies in the general obstetric population and that this test can also detect other chromosomal abnormalities (additional findings). However, evidence regarding the clinical impact of screening for additional findings is lacking. Full-Text PDF Open Access